20
2020-12
Kintor Pharma's shares have been included in FTSE Index
Suzhou, Dec. 20, 2020--Kintor Pharmaceutical Limited is pleased to announce that the company‘s shares have been included in FTSE Global Equity Index Series micro-cap index, with effective after the close of business on December 18.
11
2020-12
Preliminary Results from the Proxalutamide's COVID-19 Trial
Suzhou, Dec. 11, 2020--Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the Clinical Trial of Proxalutamide for the treatment of COVID-19.
09
2020-12
Kintor to Present Results of GT90001 and Opdivo Combo Study at 2021 ASCO GI
On December 9, 2020, Kintor has announced to present results of GT90001 and Opdivo combo study at 2021 ASCO GI.
25
2020-11
Female Subjects Included in Clinical Trial of Proxalutamide Treating COVID-19
Kintor Pharmaceutical Limited announced that the clinical trial of Proxalutamide in the treatment of COVID-19 was based on the positive results preliminarily shown in the treatment of male subjects.
25
2020-11
Kintor Pharmaceutical’s SMO Antagonist Obtains Approval of Clinical Trial from FDA
Kintor Pharmaceutical Limited announced that its SMO antagonist GT1708F was approved by the US Food and Drug Administration for clinical trials, and the treatment of basal cell carcinoma will be commenced.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn